One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Why and How Smoking Cessation Must Be Implemented in Urology Clinics as a Standard of Care
AndresAffentrangerabRichard S.MatulewiczcChristian D.Fankhausera
Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies
Rebecca E.Graffab1Kathryn M.Wilsona1AlejandroSanchezcSteven L.ChangdeDavid F.McDermottfToni K.ChoueirieEunyoungChoghiSabinaSignorettijEdward L.GiovannucciagkMark A.Prestonde
Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer
Veerle H.GroenaKarinHaustermansbFloris J.PoscCédricDraulansbSofieIsebaertbEvelyn M.MonninkhofcRobert J.SmeenkdMartinaKunze-BuschdJohannes C.J.de BoeraJochemvan der Voort van ZijpaLinda G.W.KerkmeijeradUulke A.van der Heidee
Simultaneous Integrated Micro-boost: Reigniting the FLAME for Dose Escalation in Prostate Cancer?
Zachary S.Zumsteg*
Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound
Iris E.ErtlaUrsulaLembergeraDafinaIlijaziaMelanie R.HassleraAndreasBruchbacheraRobertBrettneraHannahKronabitteraMichaelGutmannbPetraVicianbGerhardZeitlerbAnnaKorendCharles-HuguesLardeaudThomasMohrbAndreaHaiteleEvaCompérateAndréOszwaldeGabrielWasingereThomasClozelfg…Shahrokh F.Shariataijklm
Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer
SamanthaConroyabAlana H.T.Nguyenc
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial
EmmaHalla†Syed A.Hussainb†NuriaPortaaRebeccaLewisaMalcolmCrundwellcPeterJenkinsdChristineRawlingseJeanTremlettfThiagarajanSreenivasangJanWallacehIsabelSyndikusiDeniseSheehancAnnaLydoneRobertHuddartaj‡NicholasJamesaj‡BC2001 Investigators
Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001
Abhishek A.SolankiaMax R.KatesbPhuoc T.Tranc
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
Sumanta K.PalaJavierPuentebDaniel Y.C.HengcHilaryGlendPiotrKoralewskieDaniilStroyakovskiyfBorisAlekseevgFrancisParnishDanielCastellanoiTudorCiuleanujJae LyunLeekKaisaSunelalKarenO'HaramTerri A.Bindern†LixianPengn‡Alan D.SmithmSun YoungRhao
Treatment Strategies in Metastatic Renal Cancer: Dose Titration in Clear Cell Renal Cell Carcinoma
Janet E.BrownaStefan N.Symeonidesb
Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer
ZhiwenChen†PengHe†XiaozhouZhou†PengLiQianweiLiJiZhengXuemeiLiZhansongZhou
Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling
Wayne G.Brisbanea†Alan M.Priesterb†JorgeBalloncLornaKwanbMerdie K.DelfinbEly R.FelkerbAnthony E.SiskbJim C.HudLeonard S.Marksb
The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial
Rebecka ArnsrudGodtmanabKarin StinesenKollbergaCarl-GustafPihlcMarianneMÃ¥nssonaJonasHugossona
A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging–directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men
Ivo M.Wagensvelda†Daniel F.Ossesab†Pieter M.GroenendijkcFrank M.ZijtadMartijn B.BusstrabeElenaRociufJelle O.BarentszgJ.P.Michiel SedelaarhBerberArbeeliTonRoeleveldjRemyGeenenkIngridKoeterlSaskia A.van der MeermVincentCappendijknRikSomfordoSjoerdKlaverpHansVan der LelyqTinekeWoltersr…Ivo G.Schootsav
Re: The Impact of COVID-19 Vaccine on Sperm Quality
Walter D.Cardona MayaaTemidayo S.OmolaoyebStefan S.du Plessisbc
Re: Effect of a Smoking and Alcohol Cessation Intervention Initiated Shortly Before Radical Cystectomy—the STOP-OP Study: A Randomised Clinical Trial
AndresAffentrangerabRichard S.MatulewiczcChristian D.Fankhauserab
Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial
SolaAdelekeabBorisToccobVeeruKasivisvanathanc
Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma
ElisabethGrobet-JeandinabUgoPinaraMorganRouprêta
Re: Phase II Trial of Cabozantinib Plus Nivolumab in Patients with Non-clear-cell Renal Cell Carcinoma and Genomic Correlates
YunzeXuYiranHuangJinZhang
Re: Trends in Incidence of Metastatic Prostate Cancer in the US
BernardoRoccoabMaria ChiaraSighinolfiabRafael FerreiraCoelhocMarcioCovas MoschovasdeVipulPatelde
Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma
JavierLanillosaMarÃaSantosaCarlosValdiviaaAlbertoMoraaCristinaRodrÃguez-Antonaab
Urologists and Kidney Transplantation: The First European Census
AlessioPecoraroaVincenzoLi MarziaFrancescoSessaaRomainBoissierbVitalHeviacThomasPrudhommedIuliaAndraseAlbertoBredafSergioSerniagAngeloTerritoe†RiccardoCampiag†EAU Young Academic Urologists Working Group on Kidney Transplantation
Re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503–14
RuobingLeiaYuehuanLibYaolongChenac
Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen’s Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503–14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates
KatharinaBeyeraStevenMacLennanbMiekeVan Hemelrijcka
Re: Christian Radmayr’s Words of Wisdom re: Fertility Potential Is Compromised in 20% to 25% of Boys with Nonsyndromic Cryptorchidism Despite Orchidopexy Within the First Year of Life. Eur Urol. 2022;82:143
FarukHadziselimovicaGilvydasVerkauskasbGuyBogaertc
Re: Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland. Thulium Fibre Laser Versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. 2022;82:73–79: The Thulium Fibre Laser in Ureteroscopic Lithotripsy: Prospect and Risk Coexist?
JinzeLiab†YinHuangab†DehongCaoaQiangWeia
Reply to Jinze Li, Yin Huang, Dehong Cao, and Qiang Wei’s Letter to the Editor re: Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland. Thulium Fibre Laser Versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. 2022;82:73–79
ØyvindUlvikabMathiasSørstrand ÆsøyaPatrickJuliebø-JonesabPederGjengstøaChristianBeislandab
Re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407–13
FrancescoMontorsiArmandoStabileElioMazzoneGiorgioGandagliaAlbertoBriganti
Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia, and Alberto Briganti’s Letter to the Editor re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407–13
DeepikaReddyabHashim U.Ahmedabcd
Re: J. Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331–6: Novel Insights into Evidence of Metastatic Urothelial Carcinoma Transcriptomic Subtype
YuxuanSongCaipengQinTaoXu
Reply to Yuxuan Song, Caipeng Qin, and Tao Xu’s Letter to the Editor re: J. Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. Eur Urol 2022;81:331–6
J. AlbertoNakauma-GonzálezabcMaudRijnderscHarmen J.G.van de WerkenabdMartijn P.J.LolkemacJoost L.Boormansb
Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106–14
YongfengLaoYananWangZhilongDong
Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong’s Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106–114
Amar U.KishanabDaniel E.Sprattc
Re: Benjamin Pradere, Richard Mallet, Alexandre de La Taille, et al. Climate-smart Actions in the Operating Theatre for Improving Sustainability Practices: A Systematic Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.027
MichaelBaboudjianPietroDianaAlbertoBreda
Re: Caelán Max Haney, Maximilian C. Kriegmair, Maurice Stephan Michel, Jens-Uwe Stolzenburg, Karl-Friedrich Kowalewski. New Evidence and Innovative Approaches to Blinding in Robot-assisted Radical Cystectomy. Eur Urol. 2022;81:615–617
FabrizioDi MaidaaAlessandroLarcherbPaoloDell'OgliocdeAndreaMinerviniaJunior ERUS / Young Academic Urologist Working Group on Robot-assisted Surgery
Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006
YongbaoWeiRuochenZhangLeLin
Corrigendum to “Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer� [Eur Urol 2021;80:567–72]
Andrew J.Vickers
